ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M

Core Insights - Esperion Therapeutics (ESPR) has entered into a definitive agreement to acquire Corstasis Therapeutics for up to $75 million in cash, which is expected to enhance its cardiovascular portfolio [1][3][6] - The acquisition includes Corstasis' lead product, Enbumyst, the first FDA-approved nasal spray diuretic for treating edema associated with congestive heart failure and other conditions [2][6] - The deal is anticipated to close in the second quarter of 2026, subject to customary conditions [2] Financial Details - The upfront payment for the acquisition is $75 million, with potential additional payments of up to $180 million based on regulatory and sales milestones, along with low double-digit royalties on net sales of Enbumyst [3][6] - Esperion plans to fund the acquisition through existing credit facilities and monetizing Japanese royalties [7] Strategic Fit - The acquisition is seen as a strategic fit for Esperion, expected to broaden its commercial portfolio and accelerate double-digit revenue growth [4][6] - The addition of Enbumyst is projected to help Esperion target a market opportunity exceeding $4 billion in the United States [10] Current Portfolio - Esperion currently markets two FDA-approved drugs, Nexletol and Nexlizet, which have seen a 38% increase in net product sales in the U.S. to $115.8 million in the first nine months of 2025 [8][9] - These drugs are marketed under different names in ex-U.S. markets, and the company earns royalties on their sales [9]